查詢結果分析
相關文獻
- Does Transarterial Embolization Improve Survival for Recurrent Hepatocellular Carcinoma after Living Donor Liver Transplantation?
- 肝癌破裂的臨床經驗與預後因子之分析
- Efficacy of a Stress Management Program for Patients with Hepatocellular Carcinoma Receiving Transcatheter Arterial Embolization
- 肝癌病患對疾病及肝動脈栓塞療法的調適策略之探討
- Ruptured hepatocellular Carcinoma: Treatment Strategy and Prognostic Factor Analysis
- Three Dimensional Conformal Rabiotherapy for Portal Vein Tumor Thrombosis in Advanced Hepatocellular Carcinoma
- 肝臟移植的現況與未來的發展
- 肝臟移植
- 肝癌的經動脈栓塞療法
- 自發性破裂肝癌的手術治療:並強調經導管肝動脈栓塞後之肝切除
頁籤選單縮合
題名 | Does Transarterial Embolization Improve Survival for Recurrent Hepatocellular Carcinoma after Living Donor Liver Transplantation?=動脈栓塞治療是否可以改善活體肝臟移植後肝癌復發的存活期? |
---|---|
作 者 | 陳韋廷; 余俊彥; 黃棟樑; 陳泰益; 曾亮節; 歐信佑; 陳肇隆; 鄭汝汾; | 書刊名 | Journal of Radiological Science |
卷期 | 37:3 2012.09[民101.09] |
頁次 | 頁101-104+a8 |
分類號 | 416.246 |
關鍵詞 | 動脈栓塞; 肝臟移植; 肝癌; |
語文 | 英文(English) |
英文摘要 | Hepatocellular carcinoma (HCC) is the second leading cause of cancer related death in Taiwan. However, HCC recurrence after living donor liver transplantation (LDLT) is an undesirable outcome, and the treatment is controversial due to different recurrent patterns. The aim of this study is to evaluate the efficacy of transarterial embolization (TAE) for HCC recurrence after LDLT. From March 2003 to February 2011, 217 patients received LDLT for HCC under Milan/UCSF criteria in Kaohsiung Chang Gung Memorial Hospital. The clinical profiles, imaging features, histopathologic diagnosis, treatment methods and outcomes of HCC recurrence after LDLT were retrospectively analyzed. TAE was performed with a microcatheter system to protect hepatic artery anastomosis. The endpoint of this study was survival from time of recurrence. Recurrences were found in 15 patients (6.9%) with LDLT for HCC, and were divided into three groups by treatment. Group 1 (n=2) was surgical resection for localized extrahepatic recurrence. Group 2 (n=4) was TAE for intrahepatic recurrence. Group 3 (n=9) was systemic chemotherapy, radiation therapy or conservative treatment for multiple intrahepatic or extrahepatic recurrence. Kaplan-Meier survival estimates showed that the 6- and 12-months survival after recurrence in group1, 2, 3 was 100%, 75%, 55.5% and 100%, 37.5%, 0% Surgery had significant benefit on survival after recurrence for solitary or localized resectable recurrence. TAE may have an effect in the loco-regional control of intrahepatic recurrence to prolong survival, even where limited extrahepatic metastasis could be controlled by other treatment. Multiple metastasis was usually unresponsive to chemotherapy and/or radiation therapy with shorter survival after recurrence. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。